Study guide
3.1 The Bone Mass Measurement Act: Covered Indications and Coding
ARRT Bone Densitometry Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Orientation & the ARRT Blueprint
1.1 About the ARRT Bone Densitometry Examination 1.2 Eligibility, Structured Education, and Clinical Experience
2 Chapter 2: Osteoporosis, Bone Biology & Risk Factors
2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria 2.2 Bone Functions, Structural Anatomy, and Bone Types 2.3 Bone Cells, the Remodeling Cycle, and Calcium Homeostasis 2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
3 Chapter 3: Indications, Prevention & Treatment
3.1 The Bone Mass Measurement Act: Covered Indications and Coding 3.2 Prevention: Nutrition, Exercise, Smoking Cessation, and Fall Prevention 3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
4 Chapter 4: Patient Preparation, Support & Radiation Safety
4.1 Patient Support, Disabilities, Ergonomics, and Transfer Techniques 4.2 Patient Instructions: Explaining the Exam, Dose, Duration, and Motion Control 4.3 Patient History, Contraindications, and Pregnancy Screening 4.4 Scan Preparation: Patient Data Entry, Artifact Removal, and Infection Control 4.5 Radiation Safety in DXA: ALARA, Distance, and Dose Levels
5 Chapter 5: DXA Physics & Instrumentation
5.1 Physical Principles of Dual-Energy X-ray Absorptiometry 5.2 Beam Geometries: Pencil Beam and Fan Beam Systems 5.3 Fan-Beam Geometry: Source–Object–Detector Distances, Magnification, and Centering 5.4 The Scan Analysis Algorithm: Soft Tissue, Bone Edge Detection, BMC, Area, and BMD
6 Chapter 6: Measuring & Reporting Bone Mineral Density
6.1 Statistics for Densitometry: Mean, Standard Deviation, and Coefficient of Variation 6.2 T-Scores, Z-Scores, and Reference Database Selection 6.3 Clinical Indications for BMD Testing and the FRAX Tool 6.4 Vertebral Fracture Assessment and Trabecular Bone Score 6.5 Whole Body DXA, Body Composition, and Pediatric Scanning
7 Chapter 7: Quality Control, Precision & Equipment Management
7.1 Accuracy, Precision, and the Sources of Precision Error 7.2 Daily Quality Control, Phantoms, and Control Charts 7.3 In Vivo Precision Studies and RMS-SD Calculation 7.4 Determining and Applying the Least Significant Change 7.5 Maintenance, Repair, Relocation, Cross-Calibration, and Software Upgrades
8 Chapter 8: DXA Informatics & Data Management
8.1 DXA Informatics, DICOM, PACS, and Data Management
9 Chapter 9: Lumbar Spine DXA
9.1 Lumbar Spine Anatomy, Landmarks, and Regions of Interest 9.2 Lumbar Spine Scan Acquisition and ROI Edge Placement 9.3 Lumbar Spine: Compensating for Body Habitus, Variant Anatomy, Pathology, and Low Bone Density 9.4 Lumbar Spine Positioning: The Leg Block, Centering, and Common Challenges 9.5 Lumbar Spine Problems: Poor Bone Edge Detection and Obscured Intervertebral Spaces 9.6 Lumbar Spine: Variant Anatomy, Fractures, Degenerative Pathology, Calcification, and Surgery 9.7 Lumbar Spine Analysis: Vertebral Exclusion and Reporting Rules 9.8 Lumbar Spine Follow-Up Scans and Rate of Change
10 Chapter 10: Proximal Femur DXA
10.1 Proximal Femur Anatomy, Landmarks, and Regions of Interest 10.2 Femur Selection: Right, Left, and Dual Femur Scanning 10.3 Proximal Femur Scan Parameters and Compensation 10.4 Proximal Femur Positioning: Neck Rotation, Shaft Placement, and Positioning Aids 10.5 Proximal Femur Problems: Ischium, Short Neck, Arthritis, Fracture, and Hardware 10.6 Femoral ROI Analysis: Femoral Neck, Total Hip, and Ward's Area 10.7 Proximal Femur Follow-Up Scans and Rate of Change
11 Chapter 11: Forearm DXA
11.1 Forearm Anatomy, Landmarks, and Adjacent Structures 11.2 Forearm Indications and Side Selection 11.3 Forearm Length Measurement, Scan Parameters, and Positioning 11.4 Forearm Regions of Interest: One-Third, Mid, Ultradistal, and Total 11.5 Forearm Problems: Edge Detection, Artifacts, Low Bone Density, and Joint Disease 11.6 Scan Analysis: Region Placement, Window Level, and Reported Values 11.7 Forearm Follow-Up Scans and Rate of Change
12 Chapter 12: Cross-Site Artifacts & Clinical Integration
12.1 Recognition, Impact, and Management of DXA Artifacts 12.2 Clinical Interpretation, Serial Comparison, and Reporting
3.1 The Bone Mass Measurement Act: Covered Indications and Coding
Key Takeaways Explain This Topic AI
The Bone Mass Measurement Act established Medicare Part B coverage for bone mass measurement, implemented under 42 CFR 410.31 effective July 1, 1998.
Five categories qualify: estrogen-deficient women at clinical risk, individuals with vertebral abnormalities on x-ray, individuals on glucocorticoids averaging 5.0 mg prednisone or more daily for more than 3 months, individuals with primary hyperparathyroidism, and individuals being monitored on FDA-approved osteoporosis drug therapy.
The standard frequency permits a covered bone mass measurement when at least 23 months have passed since the month of the last measurement.
More frequent testing is permitted for long-term glucocorticoid therapy exceeding 3 months and for a confirmatory baseline when the initial measurement used a different technology.
Coverage requires a physician or qualified nonphysician practitioner order, appropriate physician supervision, and FDA-cleared measurement equipment.
Last updated: September 2026
3.1 The Bone Mass Measurement Act: Covered Indications and Coding
Quick Answer: The Bone Mass Measurement Act created Medicare Part B coverage of bone density testing, codified at 42 CFR 410.31 and effective July 1, 1998 . Coverage requires a physician order, appropriate supervision, FDA-cleared equipment, and membership in one of five qualifying categories . The standard frequency is one covered measurement when at least 23 months have passed since the month of the last one, with two defined exceptions.
Why the Technologist Owns This Topic
Coverage rules are a named ARRT content item, and for a working reason: the technologist is usually the last person to see the requisition before the scan happens. If the order lacks a qualifying indication, or if the patient's last scan was 14 months ago and no exception applies, the scan will be performed and then denied. The patient receives the radiation, the facility absorbs the cost, and the technologist is the person who could have caught it.
Statutory Background
The Bone Mass Measurement Act was enacted as part of the Balanced Budget Act of 1997 and implemented through the regulation at 42 CFR 410.31 , effective July 1, 1998. Before it, Medicare coverage of bone density testing varied by carrier. The Act standardized coverage nationally and, critically, defined it by patient category rather than by diagnosis code alone .
The regulation defines a bone mass measurement as a radiologic, radioisotopic, or other procedure performed to identify bone mass, detect bone loss, or determine bone quality, using a bone densitometer or bone sonometer system that has been cleared or approved by the FDA, and that includes a physician's interpretation of the results.
Three conditions apply to every covered study regardless of category:
It is ordered by a physician or qualified nonphysician practitioner who is treating the beneficiary.
It is performed under appropriate physician supervision .
It is reasonable and necessary for diagnosing and treating the beneficiary's condition.
The Five Qualifying Categories
# Qualifying individual
1 A woman determined by her treating physician or qualified nonphysician practitioner to be estrogen-deficient and at clinical risk for osteoporosis
2 An individual with vertebral abnormalities demonstrated by x-ray to be indicative of osteoporosis, osteopenia, or vertebral fracture
3 An individual receiving, or expecting to receive, glucocorticoid (steroid) therapy equivalent to an average of 5.0 mg of prednisone or greater per day for more than 3 months
4 An individual with primary hyperparathyroidism
5 An individual being monitored to assess response to, or efficacy of, an FDA-approved osteoporosis drug therapy
Two details in this list generate exam items:
Category 3 is 5.0 mg of prednisone equivalent or greater, averaged daily, for more than 3 months. The same threshold appears in the FRAX glucocorticoid input and in clinical guidelines for glucocorticoid-induced osteoporosis, which is convenient — one number covers three topics. It is an average , so alternating high-dose and low-dose regimens still qualify if the average clears 5.0 mg.
Category 4 specifies primary hyperparathyroidism. Secondary hyperparathyroidism, which is common in chronic kidney disease and vitamin D deficiency, is not the named category. Primary hyperparathyroidism preferentially attacks cortical bone, which is why forearm imaging matters in these patients.
Note also what is absent : there is no age-based screening category. A healthy 68-year-old woman with no risk factors is covered under universal screening guidance from professional societies, but the Medicare category she satisfies is category 1 only if her physician documents estrogen deficiency and clinical risk. Coverage categories and clinical practice guidelines are related but not identical, and confusing them is a classic distractor.
Frequency: The 23-Month Standard
Medicare may cover a bone mass measurement when at least 23 months have passed since the month the last bone mass measurement was performed .
The number is 23, not 24. The regulation counts from the month of the prior study, and the 23-month construction means a patient scanned in March of one year becomes eligible again in February two years later rather than in March. In practice this gives scheduling a one-month cushion and prevents denials caused by a study drifting a few days early.
Exceptions Permitting More Frequent Testing
The regulation allows measurement more often than every 23 months when medically necessary, and names two circumstances:
Monitoring beneficiaries on long-term glucocorticoid therapy of more than 3 months' duration. Glucocorticoid-induced bone loss is fastest in the first 6 to 12 months of treatment, so annual or semiannual monitoring is clinically justified.
Confirming a baseline measurement to permit future monitoring, when the initial measurement was not performed with dual-energy x-ray absorptiometry — that is, when the baseline used a different technology such as peripheral DXA or quantitative ultrasound and a central DXA baseline is needed before serial monitoring can be meaningful.
The second exception is the one technologists encounter most often. A patient screened at a health fair with a heel sonometer arrives with an abnormal result; a confirmatory central DXA is covered even though a "bone mass measurement" was performed weeks earlier, because the two technologies are not comparable and no valid baseline exists.
Practical Documentation and Coding Notes
Bone density services are reported with dedicated CPT codes distinguishing axial DXA (lumbar spine and hip), appendicular DXA (forearm, heel), and vertebral fracture assessment . Facilities bill technical and professional components; the technologist's role is ensuring the documentation supports the study actually performed.
The scan performed must match the scan ordered. If the order specifies axial DXA and the spine is unanalyzable, adding the forearm requires contacting the ordering provider rather than substituting silently.
Record the qualifying indication. The requisition should carry the category or the supporting diagnosis; a requisition reading only "osteoporosis screening" is a frequent denial source.
Document prior study dates. Knowing the month of the last measurement, and on which device it was performed, determines both coverage and whether serial comparison is even valid.
A patient may still elect a non-covered scan as a self-pay study; the facility's Advance Beneficiary Notice process, not the technologist, governs that conversation.